In 2018, the National Institute on Aging-Alzheimer’s Association (NIA-AA) reported that the highest probability of identifying AD pathology in vivo is achieved by combining markers of Aβ (A) and p-tau (T) pathology [1]. This evidence concerns the gene MAPT and Alzheimer disease.